{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parsons HA"],"funding":["NCI NIH HHS"],"pagination":["896-903"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9848583"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5"],"pubmed_abstract":["<h4>Purpose</h4>Human epidermal growth factor receptor 2 (HER2)-directed treatments improve outcomes for patients with HER2-positive metastatic breast cancer (MBC). Current identification of patients with HER2-positive disease relies on tumor tissue testing, which can be inaccurate because of tumor heterogeneity or tumor evolution. Circulating tumor cells (CTCs) are often present in patients with cancer. We hypothesized that HER2 assessment of CTCs in patients with HER2-negative breast cancer could identify a subset of patients with HER2-positive CTCs who could benefit from HER2-directed treatments.<h4>Methods</h4>This was a single-arm, two-stage, phase II trial. Patients with HER2-negative progressive MBC with HER2-positive CTC (defined as HER2/CEP17 ratio ≥ 2.0 by fluorescence in situ hy"],"journal":["JCO precision oncology"],"pubmed_title":["Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells."],"pmcid":["PMC9848583"],"funding_grant_id":["K08 CA252639"],"pubmed_authors":["Barry WT","Tayob N","Li T","Guo H","Parsons HA","Macrae ER","Wulf GM","Isakoff SJ","Krop IE"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.","description":"<h4>Purpose</h4>Human epidermal growth factor receptor 2 (HER2)-directed treatments improve outcomes for patients with HER2-positive metastatic breast cancer (MBC). Current identification of patients with HER2-positive disease relies on tumor tissue testing, which can be inaccurate because of tumor heterogeneity or tumor evolution. Circulating tumor cells (CTCs) are often present in patients with cancer. We hypothesized that HER2 assessment of CTCs in patients with HER2-negative breast cancer could identify a subset of patients with HER2-positive CTCs who could benefit from HER2-directed treatments.<h4>Methods</h4>This was a single-arm, two-stage, phase II trial. Patients with HER2-negative progressive MBC with HER2-positive CTC (defined as HER2/CEP17 ratio ≥ 2.0 by fluorescence in situ hy","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-04T08:33:36.673Z","creation":"2025-04-04T08:33:36.673Z"},"accession":"S-EPMC9848583","cross_references":{"pubmed":["34994617"],"doi":["10.1200/po.20.00461","10.1200/PO.20.00461"]}}